# Nuclide record nct04557059 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct04557059/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct04557059", "NCT04557059" ;
  schema:name "A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer"@en ;
  schema:alternateName "PRIMORDIUM"@en ;
  schema:description "A phase 3 trial of Apalutamide in prostate cancer, run by Janssen Pharmaceutica N.V., Belgium, active and no longer recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct04557059/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04557059> ;
  nuclide:status "active" ;
  nuclide:tag "pipeline", "ctgov-ingest" ;
  nuclide:phase "3" ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/prostate-high-risk/> ;
  nuclide:companies <https://nuclide.cc/companies/johnson-johnson/> .